2019 logo_150x35_jpg.jpg
Novan Receives Phase 2 NIH Federal Grant of Approximately $1.0 Million
February 20, 2020 08:15 ET | Novan, Inc.
Provides funds to evaluate the mechanistic antiviral activity of WH602Novan to progress IND-enabling toxicology and pharmacology studies for WH602 Grant is additive to $223,000 Phase 1 NIH grant...
2019 logo_150x35_jpg.jpg
Novan Awarded Approximately $1.1 Million Grant by Department of Defense
September 20, 2019 08:30 ET | Novan, Inc.
Funds to progress women’s health product candidate, WH504Additive to recently announced NIH grant for WH602Women’s health initiative to focus on potential HPV related onco-virus therapeutics ...
2019 logo_150x35_jpg.jpg
Novan Advances Women’s Health Business Unit with Non-Dilutive Funding
August 14, 2019 08:15 ET | Novan, Inc.
Company has received NIH federal grant of approximately $223,000Anticipates additional federal grant of approximately $1.0 millionWomen’s health initiative to focus on potential HPV related onco-virus...
novan logo.jpg
Novan Creates Dedicated Women’s Health Business Unit
October 25, 2018 07:05 ET | Novan, Inc.
Business unit will focus on Novan’s proprietary nitric oxide technology and its application to target high-risk human papillomavirus (HPV) and associated cancers affecting women such as cervical...